Compare Mitsubishi UFJ Financial Group Inc. Common Stock (MUFG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mitsubishi UFJ Financial Group Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $21.69 (market cap $252.11B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 4.4× Natera Inc. Common Stock's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays a 2.41% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 2 Days and Natera Inc. Common Stock for 0 Days on average.
| MUFG | NTRA | |
|---|---|---|
Market Cap | $252.11B | $57.03B |
Volume | 3,452,336 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $24.13 | $425.64 |
52-Week Low | $14.77 | $179.42 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $29.18T | $56.18B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MUFG trades at $22.40, up 0.22% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 exceeding the $0.35 estimate. Fundamentals show robust profitability with a 34.22% net income margin and 12.6% ROE, while valuation ratios like a P/E of 14.99 appear reasonable. Recent news highlights a partnership with SkyDrive for eVTOL feasibility studies and positive analyst momentum coverage.
The outlook is supported by earnings momentum and a 100% buy rating from analysts, but risks include a high debt-to-asset ratio of 5.81 and significant negative cash flow trends. Investor sentiment is optimistic due to strong quarterly results and institutional interest, though technical weakness and macroeconomic sensitivity pose near-term challenges.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mitsubishi UFJ Financial Group Inc. Common Stock
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
